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Abstract
Background: We have shown previously that Chlamydophila pneumoniae contains a dual-specific
Ser/Thr protein kinase that phosphorylates CdsD, a structural component of the type III secretion
apparatus. To further study the role of PknD in growth and development we sought to identify a
PknD inhibitor to determine whether PknD activity is required for replication.
Results: Using an in vitro kinase assay we screened 80 known eukaryotic protein kinase inhibitors
for activity against PknD and identified a 3'-pyridyl oxindole compound that inhibited PknD
autophosphorylation and phosphorylation of CdsD. The PknD inhibitor significantly retarded the
growth rate of C. pneumoniae as evidenced by the presence of very small inclusions with a reduced
number of bacteria as seen by electron microscopy. These inclusions contained the normal
replicative forms including elementary bodies (EB), intermediate bodies (IB) and reticulate bodies
(RB), but lacked persistent bodies (PB), indicating that induction of persistence was not the cause
of reduced chlamydial growth. Blind passage of C. pneumoniae grown in the presence of this PknD
inhibitor for 72 or 84 hr failed to produce inclusions, suggesting this compound blocks an essential
step in the production of infectious chlamydial EB. The compound was not toxic to HeLa cells, did
not block activation of the MEK/ERK pathway required for chlamydial invasion and did not block
intracellular replication of either Chlamydia trachomatis serovar D or Salmonella enterica sv.
Typhimurium suggesting that the inhibitory effect of the compound is specific for C. pneumoniae.
Conclusion: We have identified a 3'-pyridyl oxindole compound that inhibits the in vitro kinase
activity of C. pneumoniae PknD and inhibits the growth and production of infectious C. pneumoniae
progeny in HeLa cells. Together, these results suggest that PknD may play a key role in the
developmental cycle of C. pneumoniae.
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Background
Chlamydophila pneumoniae is an important human respira-
tory pathogen that causes laryngitis, pharyngitis, bronchi-
tis and community acquired pneumonia [1] and has been
associated with exacerbation of asthma [2,3], atheroscle-
rosis [4-6], arthritis [2,7], Alzheimer's disease [8,9] and
Multiple Sclerosis [10-13]. The ability of C. pneumoniae to
remain viable within lung macrophages [14-16] provides
a mechanism for dissemination of Chlamydia  to other
anatomical sites that may include the arterial wall [17]
and the brain. Rapid and successful treatment of C. pneu-
moniae  respiratory infections is therefore important to
ensure complete clearance of the bacteria in order to avoid
infections elsewhere in the body. Antibiotics such as azi-
thromycin, clarithromycin, erythromycin, and doxycy-
cline have been used to treat C. pneumoniae respiratory
infections [18]. However, clinical isolates of Chlamydia
resistant to azithromycin and erythromycin have been
reported [19], and some chlamydial species including C.
pneumoniae develop resistance to antibiotics in vitro [20-
25]. Furthermore, sub-optimal concentrations of antibiot-
ics in vivo may result in chlamydial persistence [16,26],
rendering the bacteria refractory to further antibiotic ther-
apy [27,28], and increasing the likelihood of Chlamydia
persisting in the body for months or years [29,30]. Given
that persistent chlamydial infections may lead to chronic
conditions there is a need to develop novel anti-microbi-
als to eradicate chlamydial infections.
All chlamydiae spp. exhibit a developmental cycle that
begins when an infectious elementary body attaches to
and invades a eukaryotic host cell. During invasion the EB
becomes enveloped by the host cell plasma membrane,
ultimately creating an intracellular vacuole known as an
inclusion, within which the bacterium undergoes replica-
tion. The EB next transforms into a reticulate body, a
developmental process that is characterized by reduction
of EB outer membrane proteins [31-33] and DNA
decondensation. RB are non-infectious, 2-5 times larger
than EB and metabolically active. Division of RB occurs
once every 2-3 hours for C. trachomatis and 6-7 hours for
C. pneumoniae [34-36]. A hallmark of chlamydial replica-
tion is the expansion of the host cell-derived inclusion
membrane to accommodate increasing numbers of bacte-
ria. In response to an as yet unidentified signal, RB begin
to asynchronously differentiate into infectious EB by
transformation through the IB stage that contains partially
condensed chromosomal DNA. The end of the develop-
mental cycle occurs when EB are released from the host
cell following inclusion lysis, or extrusion of the inclusion
into neighbouring cells [37]. In addition to the three
developmental forms seen during the chlamydial devel-
opmental cycle, Chlamydia may be induced to form per-
sistent bodies, a morphological state not part of normal
growth and development. The PB is an abnormally large
form of chlamydia that occurs in response to interferon-γ
[27], antibiotics [26], or iron limitation [38], and is char-
acterized by an inability to segregate into daughter cells
after genomic DNA replication. The arrest of the develop-
mental cycle at the PB stage can be reversed when the
inducer stimulus in the case of iron deprivation is
removed [38]. In addition to interferon-γ, and conven-
tional antibiotics such as β-lactams and macrolides, other
compounds exhibit bacteriostatic activity against Chlamy-
dia in cell culture. These include selective cycloxygenase
inhibitors, rottlerin and inhibitors of type III secretion
[34,38-42]. Rottlerin is a pan-specific inhibitor of eukary-
otic protein kinases and was recently shown to inhibit the
growth of C. pneumoniae in HeLa cells [40]. Rottlerin may
interfere with activation of the host MEK/ERK pathway
which has been shown to be necessary for chlamydial cell
invasion [43] and therefore indirectly cause inhibition of
chlamydial growth. Alternatively, INP0007 (compound
C1), INP0010, and INP0400, inhibitors of Yersinia type III
secretion, may target a bacterial-specific factor related to
the type III secretion system and directly abrogate chlamy-
dial growth in eukaryotic cells [39,41,44]. The identifica-
tion of novel targets may prove useful in the development
of new antimicrobials effective against chlamydiae.
Chlamydial genomic studies have identified three Ser/Thr
protein kinases, Pkn1, Pkn5, and PknD. Our laboratory
has shown previously that C. pneumoniae PknD is a dual-
specific protein kinase that autophosphorylates on threo-
nine and tyrosine residues and phosphorylates serine and
tyrosine residues of the FHA-2 domain of Cpn0712, a
putative Yersinia YscD ortholog called CdsD [45]. In this
report we show that a 3'-pyridyl oxindole compound, a
known inhibitor of Janus kinase 3 (JAK3), inhibits C.
pneumoniae  PknD activity. This compound prevented
PknD autophosphorylation and phosphorylation of
CdsD, a type III secretion apparatus protein. When added
to infected HeLa cells, the compound retarded C. pneumo-
niae  growth and significantly reduced the amount of
infectious C. pneumoniae produced suggesting that PknD
plays an important role in chlamydial replication.
Results
Identification of an inhibitor of C. pneumoniae PknD 
protein kinase activity
We have recently shown that C. pneumoniae contains three
Ser/Thr protein kinases [46] and that one of these, PknD,
phosphorylates CdsD, a structural component of the type
III secretion system (T3SS) [45]. In order to determine
whether PknD plays an essential role in Chlamydia devel-
opment, we screened an existing library of 80 small mol-
ecule kinase inhibitors, including inhibitors of eukaryotic
receptor tyrosine kinases and atypical kinases, for their
ability to inhibit PknD autophosphorylation in vitro.
Recombinant GST-tagged PknD kinase domain (GST-BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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PknD KD) was pre-incubated with 10 μM of each com-
pound and reactions initiated with the addition of kinase
assay buffer containing Mn2+ and ATP. SDS-PAGE and
Western blotting followed by autoradiography was used
to visualize the extent of PknD autophosphorylation in
the presence of each compound. Nine compounds (EMD
designations: D7, E8, F4, F5, F6, F7, G5, H10, and H11)
of the 80 tested exhibited some level of inhibition of
PknD autophosphorylation when tested at 10 μM (data
not shown). Of these nine compounds only one, com-
pound D7, a 3'-pyridyl oxindole, completely inhibited
PknD autophosphorylation. Fig. 1A shows a dose
response for PknD inhibition. At 1 μM compound D7
reduced PknD autophosphorylation by greater than 50%
(fig. 1A). Similar results were obtained with two different
lots of the inhibitor. Compound D4, a pan-specific inhib-
itor of the Janus kinase (JAK) family, did not significantly
inhibit PknD autophosphorylation at concentrations of
0.2 to 10 μM (figs. 1A and 1B). Similarly, two other JAK3
inhibitors, compounds D5 and D6, did not inhibit PknD
autophosphorylation at concentrations of 1 or 10 μM (fig.
1B).
Compound D7 is ATP competitive and therefore it has the
potential to inhibit other chlamydial enzymes that utilize
ATP as a substrate. To determine if compound D7 could
inhibit a chlamydial ATPase, we examined its effect on the
activity of CdsN, the T3SS ATPase of C. pneumoniae [47].
The activity of CdsN was 0.51 ± 0.09 and 0.43 ± 0.06
micromoles of phosphate/min/mg protein in the pres-
ence of 5 μM and 100 μM of compound D7, respectively,
compared with 0.46 ± 0.04 in the absence of compound
D7. Compound D7 did not inhibit CdsN activity suggest-
ing that it may not be a broad spectrum inhibitor of
enzymes that utilize ATP as a substrate.
To assess whether compound D7 could be used in cell cul-
ture we first exposed the compound to reducing condi-
Inhibition of PknD by compound D7 Figure 1
Inhibition of PknD by compound D7. A: compound D7, but not compound D4 or DMSO, substantially inhibited PknD 
autophosphorylation (32P-GST-PknD KD) at 5 and 1 μM, as seen by autoradiography. B: related compounds D5 and D6 did not 
inhibit PknD at 1 or 10 μM. C: 1 mM DTT and 1% Triton X-100 did not decrease inhibition of PknD by compound D7 (used at 
10 μM in all panels). DMSO (0.1%) is shown as control. D: compound D7 inhibited phosphorylation of the FHA-2 domain (32P-
His-FHA-2) of CdsD by PknD. Western blotting showed equivalent amounts of protein in each autoradiograph (lower panels).BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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tions similar to that found in eukaryotic cells, then tested
its ability to inhibit PknD. Equivalent volumes of com-
pound D7 (100 μM) and DTT (2 mM) were mixed on ice
for 15 minutes prior to testing in the kinase assay. Com-
pound D7 retained the ability to inhibit PknD autophos-
phorylation (fig. 1C) after exposure to DTT, suggesting
that it would not have decreased effectiveness under the
reducing conditions of the cell cytoplasm. To rule out the
possibility that the inhibitory effect of D7 was due to
aggregates of the compound, we tested for inhibitory
activity in the presence of 1% Triton X-100 to reduce
potential aggregates. Compound D7 retained efficacy
toward PknD in the presence of 1% Triton X-100 (fig. 1C),
indicating that the inhibition was not due to a non-spe-
cific effect of compound D7 aggregates.
We recently identified CdsD, an ortholog of Yersinia YscD,
as a substrate of PknD and showed that PknD phosphor-
ylated 2 FHA domains of CdsD [45]. We therefore exam-
ined whether compound D7 could block
phosphorylation of CdsD by PknD. Compound D7 com-
pletely blocked the phosphorylation of the CdsD FHA-2
domain by PknD (fig. 1D) indicating that, in addition to
inhibiting PknD autophosphorylation, it also inhibits
phosphorylation of CdsD.
Effect of compound D7 on the growth of C. pneumoniae 
in HeLa cells
The identification of a PknD inhibitor provides a new tool
to study the role of PknD in the developmental cycle of C.
pneumoniae. Since PknD may play a role at various times
throughout the 72 hour developmental cycle we tested the
effect of several compounds including compound D7 on
the growth of C. pneumoniae in cell culture. Compounds
were added to the cell culture media 1 hr prior to infection
with  C. pneumoniae and inclusions were visualized by
immunofluorescent (IF) staining at 72 hr. Compound D7
retarded the growth of C. pneumoniae in HeLa cells (fig. 2)
Compound D7 inhibits the growth of C. pneumoniae in HeLa cells Figure 2
Compound D7 inhibits the growth of C. pneumoniae in HeLa cells. Detection of inclusions at 72 hpi by IF microscopy 
revealed very small inclusions when C. pneumoniae-infected HeLa cells were exposed to 10 μM of compound D7, but not when 
exposed to DMSO (0.1%) or 10 μM of compounds D5 or D6. Arrows indicate representative inclusions. Inclusions were 
stained with FITC-conjugated anti-LPS monoclonal antibody containing Evan's Blue counterstain.BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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as indicated by the presence of very small inclusions at 72
h. Compounds D5, D6 and vehicle (0.1% DMSO) did not
have any effect on the development of inclusions judged
by the presence of normal size inclusions. Given that com-
pounds D5, D6 and D7 are JAK3 kinase inhibitors, and
only compound D7 affects growth of C. pneumoniae, JAK3
inhibition is not likely responsible for the decreased
chlamydial growth rate.
Compound D7 exhibits a dose-dependent but time-
independent effect on C. pneumoniae growth
To determine whether the effect of compound D7 on
chlamydial growth is dose-dependent we added com-
pound D7 to infected HeLa cells at 1 hr post infection at
final concentrations of 0.4, 2 and 10 μM and assessed
inclusion size at 72 hpi. Vehicle or 0.4 μM of D7 resulted
in normal size inclusions at 72 hr (fig. 3A). Compound
D7 at 2 μM resulted in slightly smaller inclusions relative
to DMSO-only exposure while D7 at 10 μM resulted in
very small inclusions (fig. 3A). To determine if compound
D7 exerts a time-dependent effect on Chlamydia growth,
the compound was added to infected cells at 15 and 24
hours post infection in addition to 1 hpi. Under each con-
dition inclusions were very small at 72 hpi compared to
inclusions in cells exposed to vehicle (fig. 3B) indicating
that the effect of compound D7 on Chlamydia growth is
not restricted to a time prior to 24 hpi. These results dem-
onstrate that compound D7 exerts a dose-dependent but
time-independent effect on C. pneumoniae growth in HeLa
cells.
C. pneumoniae growth inhibition by compound D7 is dose-dependent Figure 3
C. pneumoniae growth inhibition by compound D7 is dose-dependent. A: compound D7 at 0.4 μM exhibited no inhi-
bition of chlamydial growth (normal size inclusions), 2 μM exhibited partial inhibition (smaller inclusions), and 10 μM had a sig-
nificant inhibitory effect (significantly reduced inclusion size) (bottom panels, left to right, respectively). DMSO controls at 
0.004, 0.02, and 0.1% (top panels, left to right, respectively) did not restrict growth as indicated by inclusion size. Arrows indi-
cate representative inclusions. B: Addition of 10 μM compound D7 to C. pneumoniae-infected HeLa cells at 1, 15 or 24 hpi 
resulted in small inclusions at 72 hpi. Inclusions were stained with FITC-conjugated anti-LPS monoclonal antibody containing 
Evan's Blue counterstain.BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
Page 6 of 13
(page number not for citation purposes)
Compound D7 does not affect HeLa cell viability
Since inhibition of C. pneumoniae growth could be due to
an effect of compound D7 on host cell viability, we
assessed whether D7 affects HeLa cell replication and
cytotoxicity. Uninfected HeLa cells were incubated in the
presence of 10 μM compound D7 or DMSO, and cell den-
sity was assessed at 0, 22, 44 and 66 hours using a spectro-
photometric assay. Compound D7 had little or no effect
on HeLa cell growth rate compared to DMSO (fig. 4A). We
also examined cell cytotoxicity at these times using an
adenylate kinase release assay. Compound D7 exhibited
the same level of cytotoxicity as DMSO at 0, 22 and 44
hours, and only slightly higher cytotoxicity levels at 66 hr
compared to DMSO-exposed cells (fig. 4B). Therefore
compound D7 had little or no effect on HeLa cell viability
and the inhibitory effect of D7 on chlamydial growth is
not likely due to a non-specific cytotoxic effect on the host
cell.
Compound D7 does not block activation of the MEK/ERK 
pathway
It has been shown previously that activation of the MEK/
ERK pathway is necessary for chlamydial invasion of host
cells [43] and sustained activation of this pathway is
required for acquisition of host glycerophospholipids by
Chlamydia [48]. To rule out the possibility that the inhib-
itory effect of compound D7 on C. pneumoniae growth
could be due to an inhibition of the MEK/ERK pathway
Compound D7 does not reduce HeLa cell viability Figure 4
Compound D7 does not reduce HeLa cell viability. A: subconfluent HeLa cell monolayers incubated in MEM containing 
either DMSO (0.1%) or compound D7 (10 μM) with 2 μg/mL cycloheximide (+), were collected by trypsinization and the cell 
density was measured by absorbance at 800 nM at the times indicated. Compound D7 did not significantly alter HeLa cell 
number compared to DMSO alone. B: cell culture supernatant adenylate kinase activity from the samples in (A). Exposure of 
HeLa cells to 10 μM compound D7 for 44 hours was not more cytotoxic than cells exposed to DMSO. At 66 hours there was 
a small increase in HeLa cell release of adenylate kinase in the D7-exposed group. Error bars represent means plus 2 standard 
deviations.BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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we assessed the level of ERK1 and ERK2 (p44/p42 MAP
kinase, respectively) phosphorylation in the presence of
compound D7. HeLa cells exposed to either 10 or 100 μM
of compound D7 contained high levels of phosphorylated
p44 and p42 MAP kinase following EGF stimulation.
HeLa cells exposed to 10 or 25 μM U0126, a specific
inhibitor of MEK1/2, were used as control and did not
contain phosphorylated p44 or p42 MAP kinase follow-
ing EGF stimulation (fig. 5). This result demonstrates that
compound D7 does not block phosphorylation of p44/
p42 MAP kinase in HeLa cells, suggesting that chlamydial
growth inhibition caused by D7 was not due to a non-spe-
cific blockage of the MEK/ERK pathway.
Effect of compound D7 on the growth of Salmonella 
enterica sv. Typhimurium and C. trachomatis serovar D
Since compound D7 could inhibit C. pneumoniae growth
indirectly by affecting a common signaling pathway of the
host cell, we examined the effect of compound D7 on the
growth of another intracellular bacterial pathogen, Salmo-
nella enterica sv. Typhimurium SL1344. Compound D7, as
well as compounds D4, D5, D6 and DMSO, did not
inhibit Salmonella replication in HeLa cells (fig. 6A), sug-
gesting that the inhibitory effect of D7 was specific to C.
pneumoniae and not the result of interference with a com-
mon signaling pathway of the host cell related to intracel-
lular pathogens. To determine whether compound D7
was inhibiting a host signaling pathway or cellular func-
tion used by the chlamydiae spp. we examined the growth
of Chlamydia trachomatis serovar D in HeLa cells in the
presence of compound D7. Compound D7 did not
inhibit the growth of C. trachomatis in HeLa cells as
assessed by IF staining of mature inclusions present at 48
hr (fig. 6B), indicating that compound D7 is specific for C.
pneumoniae, does not inhibit C. trachomatis, and does not
block a common signaling pathway used by chlamydiae
spp.
Compound D7 does not cause chlamydial persistence and 
does not block differentiation or replication
Since the evidence indicates the inhibitory effect of com-
pound D7 on Chlamydia growth can be exerted early in the
developmental cycle (between 1-24 hpi), it is possible
that the inhibitory effect occurs at a specific stage viz. EB
to RB differentiation or RB replication. Alternatively, a
block in replication could be due to the induction of per-
sistence which occurs under conditions of limiting tryp-
tophan or iron. To determine whether compound D7
blocks chlamydial growth at a specific stage, we used elec-
tron microscopy to look for various developmental forms.
Figs. 7A and 7B show representative inclusions at 48 hpi
from C. pneumoniae-infected HeLa cells incubated in the
presence of 10 μM compound D7. These inclusions are
smaller and contain fewer bacteria compared with
chlamydial inclusions in the absence of compound D7
(figs. 7C and 7D), consistent with results seen using IF
staining. All three developmental forms of Chlamydia,
(EB, IB and RB) were seen in the presence of compound
D7, and no aberrant forms or PB were detected, indicating
that the inhibition of chlamydial growth was not due to
the induction of persistent bodies. These results show that
Compound D7 does not block activation of the MEK/ERK pathway in EGF-stimulated HeLa cells Figure 5
Compound D7 does not block activation of the MEK/ERK pathway in EGF-stimulated HeLa cells. HeLa cells incu-
bated with DMSO, compound D7 or U0126 were activated with EGF and the levels of MAP kinase phosphorylation were 
determined by Western blot using anti-phospho ERK1/2 antibody. Compound D7 at 10 and 100 μM, and DMSO at 0.1 and 1%, 
did not prevent phosphorylation of MAP kinase following EGF stimulation of HeLa cells. U0126 at 10 and 25 μM completely 
prevented phosphorylation of MAP kinase. Blots were probed with antibody to phosphorylated MAPK (upper panel), and with 
antibody to total MAPK (lower panel).BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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compound D7 attenuates Chlamydia growth by decreasing
the number of bacteria present in infected cells.
Compound D7 decreases the number and infectivity of C. 
pneumoniae progeny
To determine whether Chlamydia progeny are infectious
after exposure to compound D7, a blind passage experi-
ment was performed. C. pneumoniae-infected HeLa cells
were incubated in the presence of compound D7 or
DMSO and the cells were lysed at 72 or 84 hr. Lysates con-
taining chlamydiae were either undiluted, or diluted in
media lacking compound D7 and blind passaged onto
fresh HeLa cell monolayers. Compound D7 reduced the
number of infectious chlamydiae compared with DMSO
alone at both times by greater than 90% based on inclu-
sion counts (fig. 8). In addition to reducing the number of
inclusions, compound D7-exposed C. pneumoniae pro-
duced inclusions that were smaller in size compared to
unexposed cultures, consistent with results seen on first
passage (figs. 2, 3). These results indicate that compound
D7 decreases the number and infectivity of C. pneumoniae
progeny.
Discussion
Chlamydiae are obligate intracellular pathogens that have
a unique biphasic developmental cycle. We have previ-
ously shown that C. pneumoniae contains three Ser/Thr
protein kinases and that one of these, PknD, is a mem-
brane-associated kinase that phosphorylates CdsD, a
structural protein of the type III secretion system [45]. In
the present study we have identified a selective inhibitor
of PknD and show that this compound blocks phosphor-
ylation of CdsD in vitro, retards the intracellular growth
rate and decreases the number of infectious C. pneumoniae
produced following infection of HeLa cells.
To elucidate the role of PknD in the chlamydial develop-
mental cycle, we screened a small library of known
eukaryotic kinase inhibitors in an attempt to identify a
PknD inhibitor. In this study we show that compound D7
is a potent inhibitor of C. pneumoniae PknD activity in
vitro. PknD autophosphorylation and subsequent phos-
phorylation of the substrate CdsD were completely inhib-
ited by compound D7. When added to C. pneumoniae-
infected HeLa cells, the 3' pyridyl oxindole compound
retarded chlamydial replication. The restriction of the
developmental cycle was not due to the induction of
chlamydial persistence as seen with interferon-γ or iron
deprivation [34,38] since PB were not detected in inclu-
sions when viewed by electron microscopy. Compound
D7 also decreased the number of infectious C. pneumoniae
Compound D7 does not inhibit the growth of Salmonella enterica sv. Typhimurium or C. trachomatis serovar D in HeLa cells Figure 6
Compound D7 does not inhibit the growth of Salmonella enterica sv. Typhimurium or C. trachomatis serovar D 
in HeLa cells. A: compounds D4, D5, D6 and D7 (10 μM) or DMSO (0.1%), did not prevent replication of Salmonella enterica 
sv. Typhimurium SL1344 in HeLa cells. Compounds were added to the media 2 hours after host cell infection, and bacteria har-
vested at both 2 and 16 hpi in order to plot the fold change in colony forming units. B: compound D7 did not inhibit the growth 
of Chlamydia trachomatis serovar D. Compound D7 (10 μM) was added to cell monolayers 1 hpi and inclusions were stained at 
48 hpi. Large inclusions were seen in both D7- (bottom right panel) and DMSO-exposed (0.1%; top right panel) cells while 
small inclusions were seen for C. pneumoniae in D7-exposed cells. Arrows indicate representative inclusions. The monoclonal 
antibody contained Evan's Blue counterstain for detection of host cells.BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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upon passage suggesting that the compound interferes
with an essential step in C. pneumoniae development.
The mechanism of chlamydial growth retardation by
compound D7 is unknown but an involvement of host
cell JAK3 is unlikely because the expression of JAK3 is
restricted to the hematopoietic cell lineage [49-51] and
HeLa cells do not express JAK3. The absence of JAK3 in
Chlamydia-infected HeLa cells is supported by a recent
study that failed to detect the induction or expression of
the JAK3 substrate, STAT5, in C. trachomatis-infected HeLa
cells [52]. In addition, other potent JAK3 inhibitors (com-
pounds D4, D5 and D6) did not interfere with C. pneumo-
niae growth in HeLa cells. Therefore the mechanism of C.
pneumoniae growth retardation in HeLa cells is unlikely
due to an effect of compound D7 on JAK3 activity.
Our data also rule out an effect of compound D7 on the
MEK/ERK signaling pathway required for chlamydial
infection and intracellular growth. Activation of the MEK/
ERK pathway has been shown to be essential for chlamy-
dial invasion of HeLa cells [43], and sustained activation
of Raf-MEK-ERK-cPLA2 is also required for acquisition of
glycerophospholipids and growth by C. pneumoniae [48].
In our experiments 100 μM of compound D7 (10 fold
higher than the concentration that inhibits chlamydial
replication) did not interfere with MAP kinase phosphor-
ylation in response to EGF, indicating that compound D7
does not block activation of the MEK/ERK pathway and
that interference with this signaling pathway is not the
mechanism of compound D7-mediated growth retarda-
tion.
Since protein kinase inhibitors are known to be promiscu-
ous [53-55] and compound D7 could inhibit a kinase or
other enzyme required for the growth of C. pneumoniae, a
similar growth inhibition by compound D7 might be
expected for other intracellular bacteria. Since compound
D7 did not inhibit the growth of Chlamydia trachomatis
serovar D or Salmonella enterica sv. Typhimurium SL1344,
an effect of D7 on a common signaling pathway used by
intracellular pathogens is not likely the mechanism of C.
pneumoniae growth retardation.
Our results show that compound D7 inhibits the auto-
phosphorylation of PknD and subsequent phosphoryla-
Normal developmental forms of C. pneumoniae are found  within compound D7-exposed inclusions Figure 7
Normal developmental forms of C. pneumoniae are 
found within compound D7-exposed inclusions. At 48 
hpi, infected HeLa cells incubated in MEM containing 10 μM 
of either compound D6 or D7 were observed by TEM. A, B: 
inclusions in D7-exposed cells are smaller and contain fewer 
bacteria, but all three developmental forms (EB, IB and RB) 
of C. pneumoniae are present. C, D: C. pneumoniae inclusions 
exposed to compound D6 are normal in size and contain the 
same normal developmental forms. Size bars are indicated in 
white (500 nm). Representative micrographs indicating RB 
(arrows) and EB (arrow heads) are shown.
Compound D7 reduces the number and infectivity of C. pneu- moniae progeny Figure 8
Compound D7 reduces the number and infectivity of 
C. pneumoniae progeny. HeLa cells were infected with C. 
pneumoniae (MOI of 5) and MEM containing either DMSO 
(0.1%) or D7 (10 μM) was added at 1 hpi. Cells were lysed at 
72 hpi and chlamydial lysates diluted 10-1 and 10-2 and used to 
infect fresh HeLa cell monolayers. Infected cells were then 
incubated for 72 hours in MEM (without D7 or DMSO) and 
inclusions were stained with FITC-conjugated anti-LPS mon-
oclonal antibody. C. pneumoniae harvested from DMSO-
exposed HeLa cells produced many inclusions of normal size 
upon subsequent passage (top panels; dilution of passage indi-
cated). A substantial reduction in both the number and size 
of inclusions was seen with chlamydiae harvested from HeLa 
cells exposed to compound D7 (bottom panels). Similar 
results were obtained with undiluted chlamydial lysates and 
with lysates harvested at 84 hpi (data not shown).BMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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tion of C. pneumoniae CdsD  in vitro and significantly
retards the growth of C. pneumoniae in HeLa cells. How-
ever, our data does not allow us to state unequivocally
that the reduced rate of growth in the presence of com-
pound D7 is directly due to inhibition of PknD activity.
Our attempts to detect phosphorylated CdsD in vivo by
mass spectrometry have not been successful as it is techni-
cally difficult to harvest enough CdsD protein suitable for
this method. We are exploring other methods for detect-
ing CdsD phosphorylation in vivo as the detection of the
phosphorylation status of PknD or CdsD in the presence
of compound D7 would allow us to make a stronger link
between PknD activity and growth rate. Since C. trachom-
atis contains a PknD ortholog we might expect compound
D7 to affect C. trachomatis but this is not the case as com-
pound D7 did not affect the growth of C. trachomatis in
HeLa cells. However, the limited homology between the
catalytic domains of the PknD orthologs in C. trachomatis
and C. pneumoniae might explain the differential effect of
compound D7 on their respective growth rates. We are
presently initiating experiments to assess whether com-
pound D7 has any inhibitory effect on PknD orthologs of
other chlamydial species and to determine effects on bac-
terial replication rates.
Electron microscopic examination of Chlamydia-infected
cells exposed to compound D7 revealed the presence of
very small inclusions with significantly reduced numbers
of bacteria. Inclusions contained all 3 developmental
forms including RB, EB and IB and therefore both replica-
tion and differentiation of C. pneumoniae occurred in the
presence of D7, albeit at a reduced rate. If inhibition of
PknD is the mechanism by which compound D7 exerts its
inhibitory effect on chlamydial replication, the presence
of replicating RB in inclusions indicates that PknD activity
is not essential for bacterial replication. In this scenario
one could envisage a redundant or compensatory signal-
ing pathway that circumvents the effect of compound D7-
mediated PknD inhibition. Alternatively, PknD may be
involved in a signaling pathway indirectly related to rep-
lication and that when inhibited only slows the rate of
replication. It is also possible that PknD is an essential
enzyme required for replication, but is only partially
inhibited in cell culture by the concentration of com-
pound D7 used in our growth experiments. Indeed, it is
known that chlamydial isolates can be heterogeneous in
nature and therefore a subpopulation of Chlamydia may
have been partially resistant to the effects of compound
D7. Nonetheless, C. pneumoniae grown in the presence of
compound D7 and subsequently passaged onto fresh
HeLa cell monolayers failed to propagate and develop
inclusions suggesting PknD may also be involved in the
production of infectious bacteria. Inhibition of PknD
could manifest as multiple biological effects if there is
more than one PknD substrate, or if the affected biologi-
cal events are linked. More work is needed to elucidate the
role of PknD and the exact mechanism by which com-
pound D7 inhibits the growth and development of C.
pneumoniae. These experiments, however, will be difficult
to conduct in the absence of a genetic transformation sys-
tem for chlamydiae.
Conclusion
We have identified a novel inhibitor of C. pneumoniae
growth and development, and its biological effects may
be mediated via inhibition of PknD. It is tempting to spec-
ulate that PknD plays an essential role in the developmen-
tal cycle of C. pneumoniae, which may include a role in
replication and/or in the production of infectious prog-
eny, but this hypothesis cannot be directly tested in the
absence of a PknD knockout. The approach of using novel
chemicals in cell culture to inhibit other Ser/Thr protein
kinases of chlamydiae viz. Pkn1 or Pkn5 may prove fruit-
ful in elucidating their roles in chlamydial development.
Methods
Reagents and Cell Lines
Minimal essential medium (MEM) (Invitrogen, Burling-
ton) containing Earle's salts and L-glutamine was supple-
mented with 10% fetal bovine serum. The Calbiochem
InhibitorSelect Protein Kinase Inhibitor Library I contain-
ing 80 receptor tyrosine kinase inhibitors and atypical
kinase inhibitors was from EMD (San Diego). MP Bio-
medicals (Santa Ana) supplied radiolabelled ATP ([γ-32P]-
ATP) for the in vitro kinase assays. HeLa 229 cells were
obtained from ATCC (Manassas). Chlamydophila pneumo-
niae CWL029 and Chlamydia trachomatis serovar D were
obtained from ATCC (cat. #VR1310 and #VR885, respec-
tively). E. coli Rosetta pLysS and BL21(DE3) pLysS were
from Novagen (EMD). Epidermal growth factor (EGF)
and the MEK inhibitor U0126 were from Sigma
(Oakville). U0126 was resuspended in DMSO immedi-
ately prior to addition to cell culture in the MEK/ERK acti-
vation experiment.
Protein Expression and Purification
GST-PknD KD and His-FHA-2 were prepared as described
[45]. Key parameters for preparing active kinase domain
included cooling the E. coli cultures to 20°C prior to
induction, inducing with 0.2 mM IPTG, and harvesting
cells after 2 hours of recombinant protein expression at
room temperature.
Protein Kinase Activity
Eighty cell permeable and ATP competitive protein kinase
inhibitors were purchased from EMD (San Diego). Each
compound in the InhibitorSelect protein kinase library
was screened at 10 μM (unless otherwise noted) in an in
vitro PknD autophosphorylation assay. Briefly, each reac-
tion contained 100 ng GST-PknD KD, 20 μM ATP, 5 mM
MnCl2 and 3 μCi [γ-32P]-ATP in 25 mM HEPES buffer (pH
7.1) supplemented with 1× complete EDTA-free protease
inhibitors, unless otherwise noted. Reactions were incu-
bated for 90 min. at 33°C, terminated with SDS-PAGEBMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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loading buffer, separated by 10% SDS-PAGE and trans-
ferred to polyvinyldinedifluoride (PVDF) membrane.
Membranes were exposed to Kodak X-OMAT film for 1-12
hours at -80°C and subsequently developed using an X-
ray processor.
ATPase Activity
ATP hydrolysis by GST-CdsN purified from glutathione-
agarose beads was measured using a malachite green assay
(R & D Systems). Reaction mixtures contained 100 ng of
GST-CdsN, 4 mM ATP, 50 mM Tris-HCL pH 7.0, 5 mM
MgCl2, and 10 mM KCl. Compound D7 was added to
final concentrations of 1 μM, 5 μM, 10 μM and 100 μM.
The reaction mixture (50 μL) was incubated at 37°C for
30 min. The reaction was stopped by the addition of 10 μL
of Malachite Green Reagent A followed by 10 μL of Mala-
chite Green Reagent B and incubated at room temperature
for one minute before an OD610  reading was taken,
according to the manufacturer's instructions.
Immunofluorescent Microscopy and Chlamydia Growth 
Experiments
HeLa cells (1 × 105) on coverslips in shell vials were
infected with C. pneumoniae CWL029 (MOI of 1) using
centrifugation, and replacement media containing 2 μg/
mL cycloheximide was added at 1 hpi. Protein kinase
inhibitors (compounds D4, D5, D6 and D7) were added
to the replacement media to a final concentration of 10
μM (unless otherwise noted), for the duration of the
Chlamydia  developmental cycle (72 hours). For time
course immunofluorescence (IF) experiments, compound
D7 was added at 1, 15 and 24 hpi. For IF staining cell
monolayers were fixed in methanol for 10 minutes at 72
hpi for C. pneumoniae and at 48 hpi for C. trachomatis.
Inclusions were stained with the Pathfinder reagent, a
FITC-conjugated anti-LPS monoclonal antibody (Bio-
Rad, Mississauga) containing Evan's Blue counterstain.
Images were captured at 400× magnification using an
Olympus BX51 fluorescent microscope equipped with a
color camera (Q color 5; Olympus). To determine the
infectivity of Chlamydia grown in the presence of inhibi-
tors, HeLa cells were infected with C. pneumoniae CWL029
and grown for 72 or 84 hrs in the presence of various com-
pounds (used at 10 μM) or vehicle (DMSO 0.1%) then
cells were lysed with glass beads into fresh MEM. Serial
dilutions of lysates were used to infect fresh HeLa cells
and inclusions were stained at 72 hr as described above.
Salmonella Infection Assay
The effect of compound D7 on the growth of Salmonella
enterica sv. Typhimurium SL1344 [56] in HeLa cells was
determined using a cell invasion assay. Briefly, overnight
bacterial cultures grown in Luria-Bertani broth (LB) were
pelleted, resuspended in 1 mL PBS and diluted in DMEM
containing 10% FBS to an MOI of ~1:100. An aliquot (0.5
mL) of the bacterial suspension was added to HeLa cells
in a 24-well plate and incubated at 37°C in a 5% CO2
atmosphere for 10 minutes. The wells were then washed
3× with PBS and incubated in DMEM for an additional 20
minutes. The medium was removed and the cells were
incubated in fresh DMEM containing 100 μg/mL gen-
tamycin for 1.5 hours. Culture media was replaced with
fresh DMEM containing 10 μg/mL gentamycin and either
0.1% DMSO, or 10 μM compound D4, D5, D6 or D7. At
2 and 16 hpi, intracellular bacteria were recovered by lys-
ing HeLa cells in PBS containing 1% Triton X-100 and
0.1% SDS. Lysates were serially diluted, plated on LB
plates, incubated overnight and colonies subsequently
counted.
HeLa Cell Viability
The effect of compound D7 on HeLa cell viability was
determined. Briefly, 10 or 100 μM compound D7, or
0.1% DMSO, with or without cycloheximide in MEM, was
added to subconfluent HeLa cells in 6-well plates. At 0,
22, 44 and 66 hours supernatants were harvested and
tested for the presence of adenylyl kinase using a cytotox-
icity assay (Lonza ToxiLight® BioAssay, Rockland). The
cytotoxicity assay was performed as per the manufac-
turer's protocol. Briefly, supernatants from HeLa cell cul-
tures incubated in the presence of compound D7 or
DMSO (in MEM containing cycloheximide) were tested
for evidence of eukaryotic cell cytotoxicity. Aliquots (5 uL)
of each supernatant were mixed with 25 uL of Adenylate
Kinase Detection Reagent and samples were incubated at
room temperature for 5 minutes. Relative light units
(RLUs) were measured using a 20/20 n Single Tube Lumi-
nometer from Turner BioSystems (Sunnyvale). Assays
were conducted in triplicate for each condition. Cell mon-
olayers were washed with warm PBS. 0.75 mL of trypsin
was added to each well, and 0.75 mL of MEM was added
after complete trypsinization (trypsinization was moni-
tored by light microscopy). Each sample was thoroughly
resuspended and aliquoted into a plastic cuvette and the
cell number immediately quantitated by determining the
optical density at 800 nM [57] using a spectrophotomer.
MEK/ERK Activation
To determine whether compound D7 interferes with acti-
vation of the MEK/ERK pathway, HeLa cells were exposed
to compound D7, DMSO, or the specific MEK inhibitor
U0126, activated with EGF and then lysates tested by
Western blot for phosphorylated and total ERK as
described [43]. Briefly, subconfluent HeLa cells in 6-well
plates were serum-starved for 3.5 hours prior to incuba-
tion for 45 min. in either 0.1% DMSO, 10 or 100 μM com-
pound D7 or 10 or 25 μM U0126 in serum-free MEM.
Cells were then incubated with 100 ng/mL EGF in serum-
free MEM for 2 minutes before being scraped in 0.5 mL
ice-cold lysis buffer (50 mM HEPES pH 7.1, 150 mMBMC Microbiology 2009, 9:218 http://www.biomedcentral.com/1471-2180/9/218
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NaCl, 1 mM EDTA, 1× complete EDTA-free protease
inhibitors (Roche, Mississauga), 1× phosSTOP phos-
phatase inhibitors (Roche) and 1% Triton X-100). An
equivalent amount of protein from each sample (450 ng)
was separated by 10% SDS-PAGE and transferred to PVDF
membrane. The membrane was blocked for 1 hour in
TBS-T containing 4% BSA, and then incubated in 1:1000
anti-phospho-p44/42 MAPK (Thr202/Tyr204) antibody
(#9101, Cell Signaling Technology, Danvers) overnight at
4°C in blocking buffer. The membrane was washed 3×
with PBS containing 0.1% Triton X-100, incubated in
1:4000 goat anti-rabbit IgG HRP-conjugate antibody
(Sigma) in blocking buffer for 1 hour at room tempera-
ture, washed and developed using enhanced chemilumi-
nescence (ECL) reagents (Amersham, Piscataway). The
PVDF membrane was then stripped of antibody, blocked,
re-probed with 1:1000 anti-p44/42 MAPK antibody
(#9102, Cell Signaling Technology) and developed as
above.
Transmission Electron Microscopy
HeLa cells (1 × 106) in 9 cm2 wells of six-well plates were
infected with C. pneumoniae CWL029 at a multiplicity of
infection of 1. Compounds were added at 1 hpi and cells
harvested at 48 hpi. Cells were fixed overnight at 4°C in
0.1 M sodium cacodylate buffer containing 2% gluteralde-
hyde, embedded in araldite resin and thin sections were
viewed using a Jeol JEM 1200EX electron microscope at
12,000× magnification.
Abbreviations
EB: elementary body; ECL: enhanced chemiluminescence;
hpi: hours post infection; IB: intermediate body; IF:
immunofluorescence; LB: Luria-Burtani broth; PB: persist-
ent body; PknD: protein kinase D; RB: reticulate body;
T3SS: type III secretion system.
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